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Little is known about the reliability of G8 screening tool and the prognostic value of 
clinical parameters within the Comprehensive Geriatric Assessment (CGA) in 
clinically fit older patients with haematological malignancies. This study was 
performed to assess the reliability of G8 as a screening tool and to determine the 
predictive value of CGA items in terms of one-year overall survival (OS). G8 and 
CGA were proposed to 107 consecutive patients (65-89yrs) with haematological 
malignancies that were judged clinically fit to receive chemotherapy. Ninety patients 
were evaluable with both scales; 72% and 80% were defined as “vulnerable” when 
evaluated with G8 (≤14.5) or CGA (≥2 impairments) respectively. The area under 
ROC-curve of G8 compared to CGA was 0.749 ± 0.051. Neither G8 nor CGA total 
score were predictive of one-year OS. However, age (HR=1.09, 95%CI: 1.009-1.185; 
p=0.029), diagnosis (HR=5.99, 95%CI: 2.322-15.428; p<0.001) and cognitive status 
(HR=3.50, 95%CI: 1.132-10.849; p=0.030) were predictive of OS. We conclude that 
in our selected haematological patients 1) the G8 score does not help selecting 
patients for CGA 2) the G8 and CGA total score do not predict OS 3) in addition to 
the age and disease itself, cognitive impairment appears to be a powerful prognostic 
factor.  
 







Growing evidence suggests that a Comprehensive Geriatric Assessment (CGA) in 
older patients with malignant haemopathies helps haematologists to detect “frailty” in 
cancer patients leading to useful interventions but less useful to identify patients for 
whom chemotherapy should be avoided or reduced as it could negatively impact 
functionality, quality of life, treatment-related toxicity or survival (1, 2). However, the 
CGA is time consuming, expensive, complex, not reproducible and not helpful for an 
individual patient with a specific treatment (3). 
 
To overcome these difficulties, the G8 screening test was developed by Soubeyran 
and colleagues (4) to identify vulnerable patients who might benefit from a full CGA 
and adapted interventions. In a systematic review of a mixed population of 
oncological patients, G8 showed a good sensitivity in detecting geriatric impairments 
in multiple domains, in fact, most of these patients were identified as having geriatric 
impairments (5). However, some concerns were raised regarding the G8’s specificity, 
as many patients with no geriatric impairment were incorrectly identified as requiring 
further assessment. 
 
Today, most of the studies on the G8 screening tool have focused either exclusively 
on patients with solid tumors or on a mixed population composed of a minority with 
haematological malignancies. Only one study has focused on a heterogeneous 
population of patients with haematological malignancies (6). Nevertheless, specific 
data are lacking on the use of G8 for specific older patients with haematological 
malignancies judged clinically fit by their physicians to receive chemotherapy and the 
use of the G8 screening tool for those patients remains to be validated in a large 
cohort.  
“Fitness scoring” is particularly important in the setting of malignant hemopathies 
because most of these diseases are observed in adults above the age of 65 years 
(7). Additionally, compared to solid tumors, hemopathies can be curable diseases –
even in older patients– and it’s crucial to identify this curable population. Finally, in 
haemato-oncology, although “frail” (patients with geriatric syndrome) older patients 
are easily detected by physicians and managed in palliative units, clinically fit older 
patients are regularly over- or undertreated solely based on their age. Consequently, 
detecting the margin between “fit” (patients with a PS <2 and full functional 
autonomy) and “vulnerable” (patients who do not meet the criteria for “fit” or “frail”) 
patients is crucial because of the risks entailed by an inadequate therapeutical 
approach.  On one hand, undertreating a patient because of comorbidities – although 
these could be reversible if due to the disease itself – could prevent this patient from 
being cured. On the other hand, treating undetected “vulnerable” patients with a 
standard chemotherapy regimen could result in severe side effects ultimately leading 
to geriatric syndromes, dependence of the patient, and sometimes, life-threatening 
adverse events. 
The objectives of this study were thus a) to assess the reliability of the G8 screening 
tool compared to a full CGA in clinically fit older patients with haematological 
malignancies b) to further investigate the predictive value of G8 and different CGA 




This prospective longitudinal study was conducted in the haematology department of 
a Belgian cancer center after approval from a national Review Board. All consecutive 
volunteer inpatients, fulfilling the inclusion criteria were invited to participate and 
provided written informed consent. To fulfill the inclusion criteria, the patients 
suffering from haematological cancer had to be at least 65 years old, were informed 
about the diagnosis of malignant haemopathies, hospitalized for chemotherapy after 
their physician’s clinical judgment, and able to speak French. Patients were excluded 
if they were hospitalized in a palliative care unit, if they had geriatric syndromes such 
as dementia or were unable to achieve the assessment for physical or psychological 
reasons. Patients were screened in the first 48 hours after admission. 
Assessment procedure 
The complete assessment lasted approximately one hour and was assisted by an 
independent investigator. All patients were invited to complete the G8 screening test 
(4) and a full Comprehensive Geriatric Assessment (CGA). The CGA in this study 
included demographic data and 8 domains related to functional status (Activities of 
Daily Living (ADL) (8) and Instrumental Activities of Daily Living (IADL) (9)) risk of 
falls status (Time up and Go test (TUG) (10) and fall history during the last year (11)), 
fatigue status (Mobility-tiredness scale (Mob-T) (12)), nutritional status (Mini 
Nutritional Assessment (MNA) (13), cognitive status (Mini Mental State Examination 
(MMSE) (14) and Montreal Cognitive Assessment (MoCA) (15)), emotional status 
(Hospital Anxiety and Depression Scale (HADS) (16) and Geriatric Depression Scale 
(GDS-4) (17)), polypharmacy (18) and comorbidities (Charlson Comorbidity Scale 
(CCI) (19)). Each test was scored on a dichotomous scale, based on individual cut-off 
points reported in the literature. Patients exhibiting deficiencies in one of the tests 
within each domain were defined as impaired in this domain. In accordance with 
previous research, patients exhibiting impairments in two or more domains within the 
CGA were defined as vulnerable (20, 21). In addition, ECOG performance status (22) 
was recorded and diagnosis, initial treatment choice (full dose or reduced-dose 
chemotherapy) based on a multidisciplinary team decision, intolerance to treatment, 
death and cause of death were extracted from medical records.   
Statistical analyses 
Descriptive analysis was used to describe the participants’ baseline characteristics. 
To obtain the discriminatory power of the G8 (test instrument) for identifying ≥ two 
geriatric abnormalities on the CGA (gold standard instrument), using estimated area 
under the ROC curve on the hypothesis of equality with 0.5 and with 95% confidence 
interval as an index of predictive accuracy. Sensitivity (S) and specificity (Sp) with 
95% confidence intervals of G8 test was calculated at the cut-off score, in 
comparison with the gold standard, and in comparison with each of the domains 
within of the CGA. Kaplan-Meir survival curves were generated and groups were 
compared using the log-rank test. Each CGA variable associated with OS (P<0.1) 
was evaluated with a multivariate Cox proportional hazards model adjusting for age, 
gender, diagnosis, initial treatment choice and tolerance to treatment; adjusted 





Among the 107 eligible inpatients, 15 refused to take part in the study and 2 
completed only one screening tool, leaving 90 assessable patients, with a median 
age of 74 (65-89 years old). Table 1 shows sociodemographic details and medical 
characteristics of these patients. Fifty four percent of the patients could be classified 
as “younger”, aged between 65 and 74 years. Most patients had a favorable 
prognosis (85%) and the majority of these patients received a full dose of 
chemotherapy (66%). Only 33% of the older patients were intolerant to the treatment. 
 
Vulnerability, G8 and CGA 
Table 2 shows vulnerability of these patients in different geriatric scale. Seventy-two 
percent of the patients presented a G8 score ≥14.5 points (vulnerable). The median 
score achieved on the G8 scale was 12.5 (range 5-17). CGA identified 80% (n=72) of 
the patients as vulnerable (≥ 2 impairments). The most frequent deficit was observed 
in the evaluation of comorbidities (61%). Problems in functional status (ADL, IADL) 
occurred in 11% and 37% (28% of men and 49% of women) of the patients 
respectively. Signs of emotional difficulties (HADS) were detected among 16% of the 
patients. Cognitive impairment was detected among 31 % of the patients with the 
MMSE (<27) and among 51% with the MoCA (<26). 
 
Reliability, G8 and CGA 
Fig 1. shows the receiver operating characteristics (ROC) analysis of the G8 
compared to the CGA as the gold standard among these patients. The area under 
the ROC-curve (AUC ± SE) of the G8 was 0.749 ± 0.051. A sensitivity of 79.2% and 
a specificity of 55.6% for G8 (cut-off score ≤ 14.5) were obtained. An optimal cut-off 
score of 13.5 was found for the G8 tool, with a sensitivity of 61.1% (95% CI [49.5-
71.5]) and a specificity of 72.2% (95% CI [48.7-87.6]). The analysis of the AUC 
values of the screening instruments versus the different items within the CGA 
showed that the G8 identified nutritional difficulties (MNA; 0.887 ± 0.019) and 
locomotion difficulties (TUG; 0,874 ± 0,094) with good diagnostic accuracy; loss of 
autonomy (ADL; 0,756 ± 0.079), fatigue (Mob-t; 0,716 ± 0,046) and emotional 
difficulties (HADS; 0,798 ± 0,077) with moderate diagnostic accuracy, and fall during 
the last year (falls; 0,526 ± 0,075), cognitive impairment (MMSE; 0,623 ± 0,178 and 
MoCA; 0,669 ± 0,055), polypharmacy (number of drugs; 0,533 ± 0,048) and 
comorbidities (CCI; 0,486 ± 0,047) with poor diagnostic accuracy. 
 
Survival, G8 and CGA 
Table 3 shows the univariate association between one-year overall survival and the 
baseline and geriatric characteristics. During the first year of follow-up, 28% (n=25) of 
older patients with haematological malignancies died. The leading cause of death 
(84%) was disease progression. Only four older patients died due to treatment 
related toxicity. Using the unadjusted effects of routine parameters and CGA 
parameters, we found that the G8 impairments had no impact on one-year OS 
(p=0.988). Surprisingly, the impairment in the CGA total score also did not impact the 
one-year OS (p=0.999). Only age ≥ 75 years (p=0.010), unfavorable prognosis 
(p<0.001) and cognitive impairment measured by the MMSE and/or the MoCA 
(p=0.013) influenced the OS. After adjusting for routine clinical parameters, as shows 
in table 4, cognitive impairment (p=0.030) remained significantly associated with 
worse OS. Fig 2. shows the Kaplan-Meier overall survival between patients without 
cognitive impairment (MMSE ≥27 and MoCA ≥26) and patients with cognitive 
impairment (MMSE<27 or MoCA <26) in one-year overall survival. This figure 



















The aims of this study were to evaluate in consecutive clinically fit older patients with 
haematological malignancies the reliability of the G8 screening tool compared to a 
full CGA and to identify the predictive value of clinical CGA parameters in terms of 
one-year OS. 
 
First, it should be emphasized that our screening was performed in a population 
admitted for chemotherapy according to clinical physician’s judgment about the 
tolerance of the patients. This prospective study showed that, at the start of their 
treatment, 72% of clinically fit older patients with haematological malignancies were 
defined as vulnerable by the G8 and 80% when evaluated with the CGA (≥ two CGA 
abnormalities). This high prevalence of vulnerability confirms the findings from 
Soubeyran et al. (23) who reported 80% of vulnerable patients in their unselected 
oncology population, but with a less stringent definition of impairment (≥ one CGA 
abnormality). One could even question the need for a screening instrument in a 
haematological population, given such a high prevalence of vulnerability. 
 
As for the G8 screening tool, we found that it identified vulnerability in clinically fit 
older patients with haematological malignancies with moderate diagnostic accuracy. 
This differs from other studies which demonstrated that the G8 had a good diagnostic 
accuracy for identifying patients who might benefit from additional investigations (23). 
This discrepancy may be explained by the fact that these studies focused either 
exclusively on solid tumors, or on a mixed population with a minority of 
haematological malignancies, and that the G8 screening tool was initially validated in 
a large French oncogeriatric population (23). In this large oncologic population, the 
sensitivity (S) of the G8 was 76.6% and the specificity (Sp) was 64.4%. In our study, 
the G8 had similar S (79.2%) but a poorer Sp (55.6%) with a cut-off score of 14.5. 
This lower specificity may be explained by the high incidence of fatigue and 
nutritional problems, common in haematological patients. This is in accordance with 
our results that demonstrated that the G8 was well correlated with the nutritional 
domain of the CGA and poorly correlated with other domains, confirming its primarily 
function-based content. However, in many haematological patients, these nutritional 
problems are due to the disease itself and are often reversible with adequate 
management. This is a major issue to take into account when making therapeutical 
decisions in order to avoid under-treatment of older patients that adequate 
chemotherapy could possibly cure or significantly prolong their survival. We found 
that a better cut-off score for the G8 in this study was 13.5, yielding a moderate 
sensitivity of 61.1% and a moderate specificity of 72.2%. However, in haematological 
patients, when curable intent is possible, it is important that screening tools have a 
good specificity in order to avoid under-treatment but also a good sensitivity to avoid 
over-treatment of true “vulnerable” patients that could develop severe side effects, 
ultimately leading to geriatric syndromes and loss of autonomy. It seems, however, 
that in its current form, the G8 is not adapted to our haematological population as a 
screening tool to optimize treatment. In other words, the G8 screening tool does not 
improve patients’ health-related quality of life through adapted care and does not 
adequately select patients susceptible to tolerate optimal treatment. These results 
are very similar to those observed by Hamaker et al. (6) in a recent paper of older 
patients with haematological malignancies, demonstrating that using the G8 in a two-
stepped approach to the geriatric assessment did not appear beneficial. 
In a second part of this study, we focused essentially on the prediction of survival in 
our selected population. Surprisingly, neither the G8 nor the CGA total score 
appeared to predict one-year survival. This conclusion is in contradiction with the 
results reported by Kenis (24) and Hamaker (6) who found a significant association of 
impaired G8 with poor prognosis in a mixed population of older cancer patients (24) 
and in older patients with malignant haemopathies (6). Our discrepancy with this last 
paper can be explained by the fact that in our population, 85% of the patients had a 
favorable prognosis compared with 42% in Hamaker’s study, and the large majority 
of our patients were alive after a one-year follow-up (72%). In addition, we selected a 
population of clinically fit older patients admitted to receive chemotherapy. It is 
important to remember that, initially, the G8 screening tool was built only to predict 
the need for full CGA in older patients (23). The poor prognostic value of the CGA 
total score in our population can be explained by the fact that – in malignant 
haemopathies – other important prognostic factors related to the disease itself such 
as anemia (25), albumin level (26) or poor cytogenetics (27), which were not 
assessed in this study, have a more prominent influence on survival.   
   
A multivariable analysis was performed on the different items of the CGA and 
surprisingly, only cognitive status in the CGA had a predictive value for one-year OS. 
This result is concordant with other studies that have demonstrated that older cancer 
patients with cognitive impairment have a higher risk of death compared to those with 
normal cognitive function (28-30). These results can be easily explained. First, older 
patients with cognitive impairment are less compliant to the treatment (31).  Second, 
cognitive impairment in older patients are often associated with late-life depression 
(32) which is correlated with a poorer survival in older cancer patients (33). Third, 
older people with cognitive impairment are more frequently isolated (34), and turn 
away persons who want to help, to avoid facing their difficulties (35). Finally, it is 
increasingly reported that chemotherapeutic agents can worsen the patient’s 
cognitive status (36-38). Thus, it is obvious those patients with cognitive impairment 
at the start of chemotherapy are more vulnerable, and that their vulnerability can be 
worsened by chemotherapeutic agents (39, 40). 
 
Although our patient population size is somewhat too small to draw definite 
conclusions, as many patients with haematological malignancies die from their 
disease and rarely from comorbidities (39), our study suggests that all clinically fit 
patients without cognitive impairment could benefit from full dose chemotherapy and 
should thus be appropriately screened for such impairment. This assumption needs 
further investigation, but could be highly relevant for future treatment guidelines. 
Patients with cognitive impairment should definitely be identified and steered towards 
rehabilitation and adapted care (38), including psychological support (35). More 
generally, health services should be adapted to the needs of this vulnerable 
population (need for services to be organized at the bedside and flexibility in 
scheduling appointments). 
 
Finally, although the CGA is considered as the gold standard to improve the 
management of older patients, its content is still debated. Additionally, an excess of 
tools and cut-off scores identifying impairment in geriatric domains are found in the 
literature. In our study, we focused on two validated scales of cognitive and 
emotional status, i.e. MMSE and MoCA for cognitive status, while the MoCA is more 
sensitive to detect mild cognitive impairment that which explains the greater 
percentage of cognitive impairment measured by this scale. We chose the CCI to 
evaluate the number of co-morbidities but their severity is probably more important 
than their quantity since an accumulation of co-morbidities was not found to be a 
good predictor of the patient’s tolerance to chemotherapy (40, 41). In agreement with 
this assumption, the CIRS-G could be a more appropriate scale. The predictive 
relevance of our screening tools in terms of toxicity could not be evaluated in this 
study since the number of toxic deaths was very low in our series of clinically fit older 
haematological patients. Finally, malignant haemopathies are heterogeneous and the 
risk profile associated with non-aggressive lymphomas is substantially different from 
that of acute myeloid leukaemia’s (AML), and the disease itself has a major impact 
on survival when a multivariate analysis is performed. 
 
To our knowledge, this is the first prospective study investigating the reliability of the 
G8 to identify clinically fit patients who should benefit from a CGA, and evaluating the 
prognostic value of clinical parameters within the CGA. Our study showed that 1) G8 
score does not help selecting patients for full CGA 2) the G8 and CGA total score do 
not predict OS 3) in addition to age and the disease itself, cognitive impairment 
appears to be a powerful prognostic factor. Prospective trials are now required to 
further determine whether better identification and management of cognitive 






This research program was supported by the National Cancer Plan of Belgium 2009-
2011; grant number: NKP-24-005 (Cindy Kenos and Pr. Hans Wildfires), the Centre 
de Psycho-Oncology (Training and Research Group) of Belgium, the Institute Jules 
Bordet, the University Liber de Brielle’s, the University Catholique de Louvain, the 
Foundation Yvonne Boël and by a grant provided by the “Fonds National de la 
Recherche Scientifique – Section Télévie” of Belgium. We would like to thank 
patients who participated in this study.  
Disclosure 
The author(s) indicated no conflicts of interest. 
Author Contributions 
Study concept and design: D. Bron, Y. Libert, D. Razavi 
Data acquisition: S. Dubruille, M. Roos, S. Vandenbossche, A. Collard, M. Maerevoet 
Quality control of data and algorithms: S. Dubruille, M. Roos, S. Vandenbossche, A. 
Collard, M. Maerevoet 
Data analysis and interpretation: S. Dubruille, Y. Libert, D. Bron 
Statistical analysis: S. Dubruille 
Manuscript preparation: S. Dubruille 
Manuscript editing: S. Dubruille, Y. Libert, D. Bron 
Manuscript review: D. Bron, Y. Libert, D. Razavi, N. Meuleman, M. Maerevoet, C. 
Reynaert, A-M Etienne, S. Dubruille 
Obtained funding: C. Reynaert, D. Bron, D. Razavi, Y.Libert, A-M Etienne 
 
REFERENCES 
1. Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. Use of 
comprehensive geriatric assessment in older cancer patients: recommendations from the task 
force on CGA of the International Society of Geriatric Oncology (SIOG). Critical reviews in 
oncology/hematology. 2005 Sep;55(3):241-52. 
2. Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for 
elderly patients with a haematological malignancy--a systematic review. Leukemia research. 
2014 Mar;38(3):275-83. 
3. Extermann M, Meyer J, McGinnis M, Crocker TT, Corcoran MB, Yoder J, et al. A 
comprehensive geriatric intervention detects multiple problems in older breast cancer patients. 
Critical reviews in oncology/hematology. 2004 Jan;49(1):69-75. 
4. Soubeyran PB GC, Blanc F, Ceccaldi J, Blanc-Blisson J, Mertens C, et al. . Validation 
of a screening test for elderly patients in oncology. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 2008;26(abstr 20568 ). 
5. Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. 
Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in 
elderly patients with cancer: a systematic review. The Lancet Oncology. 2012 
Oct;13(10):e437-44. 
6. Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric 
impairments and predicts survival in elderly patients with a haematological malignancy. 
Annals of hematology. 2014 Jun;93(6):1031-40. 
7. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. 
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006 
Jan 1;107(1):265-76. 
8. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of 
ADL. The Gerontologist. 1970 Spring;10(1):20-30. 
9. Lawton MP, Brody EM. Assessment of older people: self-maintaining and 
instrumental activities of daily living. The Gerontologist. 1969 Autumn;9(3):179-86. 
10. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility 
for frail elderly persons. Journal of the American Geriatrics Society. 1991 Feb;39(2):142-8. 
11. Lamb SE, Jorstad-Stein EC, Hauer K, Becker C, Prevention of Falls Network E, 
Outcomes Consensus G. Development of a common outcome data set for fall injury 
prevention trials: the Prevention of Falls Network Europe consensus. Journal of the American 
Geriatrics Society. 2005 Sep;53(9):1618-22. 
12. Fieo RA, Mortensen EL, Rantanen T, Avlund K. Improving a measure of mobility-
related fatigue (the mobility-tiredness scale) by establishing item intensity. Journal of the 
American Geriatrics Society. 2013 Mar;61(3):429-33. 
13. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini 
Nutritional Assessment as part of the geriatric evaluation. Nutrition reviews. 1996 Jan;54(1 Pt 
2):S59-65. 
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for 
grading the cognitive state of patients for the clinician. Journal of psychiatric research. 1975 
Nov;12(3):189-98. 
15. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. 
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive 
impairment. Journal of the American Geriatrics Society. 2005 Apr;53(4):695-9. 
16. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta psychiatrica 
Scandinavica. 1983 Jun;67(6):361-70. 
17. Sheikh JI YJ. Geriatric Depression Scale (GDS): Recent evidence and development of 
a shorter version. New-york: The Haworth Press, 1986. 
18. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. 
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-
dwelling older men at risk of different adverse outcomes. Journal of clinical epidemiology. 
2012 Sep;65(9):989-95. 
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 
prognostic comorbidity in longitudinal studies: development and validation. Journal of 
chronic diseases. 1987;40(5):373-83. 
20. Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, et al. A pilot study 
of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for 
identifying disability in older patients with prostate cancer who receive androgen ablation. 
Cancer. 2007 Feb 15;109(4):802-10. 
21. Kellen E, Bulens P, Deckx L, Schouten H, Van Dijk M, Verdonck I, et al. Identifying 
an accurate pre-screening tool in geriatric oncology. Critical reviews in oncology/hematology. 
2010 Sep;75(3):243-8. 
22. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. 
Toxicity and response criteria of the Eastern Cooperative Oncology Group. American journal 
of clinical oncology. 1982 Dec;5(6):649-55. 
23. Soubeyran P BC, Goyard J, Heitz D, Cure H, Rousselot H, et al. . Validation of the G8 
screening tool in geriatric oncology: the ONCODAGE project. . Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology. 2011;29(suppl; abstr 9001). 
24. Kenis C, Decoster L, Van Puyvelde K, De Greve J, Conings G, Milisen K, et al. 
Performance of two geriatric screening tools in older patients with cancer. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 2014 Jan 
1;32(1):19-26. 
25. Stauder R, Thein SL. Anemia in the elderly: clinical implications and new therapeutic 
concepts. Haematologica. 2014 Jul;99(7):1127-30. 
26. Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, et al. Attenuated 
immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with 
diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 
2011 May;12(5):460-8. 
27. Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W, Haferlach T. The 
influence of age on prognosis of de novo acute myeloid leukemia differs according to 
cytogenetic subgroups. Haematologica. 2004 Sep;89(9):1082-90. 
28. Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, 
Nieuwenhuijzen GA, et al. Less extensive treatment and inferior prognosis for breast cancer 
patient with comorbidity: a population-based study. European journal of cancer. 2005 
Mar;41(5):779-85. 
29. Robb C, Boulware D, Overcash J, Extermann M. Patterns of care and survival in 
cancer patients with cognitive impairment. Critical reviews in oncology/hematology. 2010 
Jun;74(3):218-24. 
30. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, et al. 
Geriatric assessment predicts survival for older adults receiving induction chemotherapy for 
acute myelogenous leukemia. Blood. 2013 May 23;121(21):4287-94. 
31. Granjon C BM, Frederico D, Blanc P, Gonthier R. Is there a risk of drug accidents in 
elderly subjects with cognitive disorders? A study of 82 demented institutionalized patients. 
NPG. 2006;6(35):21-8. 
32. Li W, Muftuler LT, Chen G, Ward BD, Budde MD, Jones JL, et al. Effects of the 
coexistence of late-life depression and mild cognitive impairment on white matter 
microstructure. Journal of the neurological sciences. 2014 Mar 15;338(1-2):46-56. 
33. Wagner DC, Short JL. Longitudinal predictors of self-rated health and mortality in 
older adults. Preventing chronic disease. 2014;11:E93. 
34. Amieva H, Stoykova R, Matharan F, Helmer C, Antonucci TC, Dartigues JF. What 
aspects of social network are protective for dementia? Not the quantity but the quality of 
social interactions is protective up to 15 years later. Psychosomatic medicine. 2010 
Nov;72(9):905-11. 
35. Dubruille S, Libert Y, Merckaert I, Reynaert C, Vandenbossche S, Roos M, et al. The 
prevalence and implications of elderly inpatients' desire for a formal psychological help at the 
start of cancer treatment. Psycho-oncology. 2014 Jul 31. 
36. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. 
Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 
1999 Feb 1;85(3):640-50. 
37. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, et al. Effect of 
adjuvant breast cancer chemotherapy on cognitive function from the older patient's 
perspective. Breast cancer research and treatment. 2006 Aug;98(3):343-8. 
38. Mandelblatt JS, Stern RA, Luta G, McGuckin M, Clapp JD, Hurria A, et al. Cognitive 
impairment in older patients with breast cancer before systemic therapy: is there an interaction 
between cancer and comorbidity? Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2014 Jun 20;32(18):1909-18. 
39. Kendal WS. Dying with cancer: the influence of age, comorbidity, and cancer site. 
Cancer. 2008 Mar 15;112(6):1354-62. 
40. Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, Machteld Wymenga AN. 
Comprehensive geriatric assessment and its clinical impact in oncology. European journal of 
cancer. 2007 Oct;43(15):2161-9. 
41. Lazarovici C KR, Leignel D, Fabre-Guillevin E, Minard A, Gisselbrecht M. Factors 
leading oncologists to refer elderly cancer patients for geriatric assessment. J Geriatr Oncol. 
2011;2:194-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
